Sperryville, VA
April 21, 2020
 
Sanford Guide and Tabula Rasa HealthCare (TRHC), a healthcare technology company advancing the field of medication safety, today announced a collaboration to make Sanford Guide easily accessible from within DoseMeRx™, TRHC’s precision dosing solution.
 
The agreement includes the addition of links to Sanford Guide’s clinically relevant anti-infective drug information and guidelines for the treatment of infectious diseases. Sanford Guide Web Edition and Sanford Guide All Access customers can now seamlessly access their subscription-based resources directly from within DoseMeRx, reducing the time needed to evaluate treatment considerations.
 
“Sanford Guide’s mission is to provide clinically actionable guidelines to providers in the most convenient way possible,” said Sanford Guide’s Vice President, Scott Kelly. “Our collaboration with Tabula Rasa HealthCare and DoseMeRx helps us achieve this by providing pertinent Sanford Guide content with a single click. We’re excited to add this time-saving feature for our mutual clients.”
 
Trusted by clinicians in more than 100 countries, Sanford Guide helps to minimize time-to-answer while providing comprehensive guidance at the point of care. Edited by distinguished infectious disease experts from leading academic and clinical centers, Sanford Guide content provides comprehensive coverage of treatment options for infectious disease, syndromes, and pathogens.
 
“Our goal is to improve patient outcomes while minimizing technology burdens on providers,” said TRHC Chairman and CEO Calvin H. Knowlton, PhD. “By making Sanford Guide available through DoseMeRx, we reduce the workload for pharmacy in healthcare organizations across the country.”
 
According to TRHC Executive Vice President for DoseMeRx, Charles Cornish, “The addition of Sanford Guide will save mutual clients using DoseMeRx crucial time in accessing the latest, updated quality clinical resources needed to enhance patient care.”

 

Sanford Guide ID Update features current developments in infectious diseases, curated by the Sanford Guide Editorial Board. Links marked with an asterisk (*) provide details to Web Edition subscribers, while all other links are universal. If you received this message from a colleague, subscribe now.
 

APRIL 2020

2020 Sanford Guide Print Editions Now Available

• The 50th Edition of The Sanford Guide to Antimicrobial Therapy was released on April 13. Books are available in three sizes. Order direct for fastest delivery.

SARS-CoV-2 / COVID-19

• Sanford Guide SARS-CoV-2 / COVID-19 material is freely available to all for the course of the pandemic.
• IDSA Guidelines on the treatment and management of patients with COVID-19 infection. Diagnostics and infection prevention coming soon.
• Guidelines on the management of critically ill adults with COVID-19, from the Surviving Sepsis Campaign COVID-19 panel (Intensive Care Med 2020 Mar 28 [Epub ahead of print]). This is a free PMC article.

Other New or Updated Treatment Guidelines

• Guidelines for community-acquired pneumonia, 2020 update, from the Spanish Society of Pulmonology and Thoracic Surgery (Arch Bronconeumol 2020;56 Suppl 1:1-10).
• Guidelines for hospital-acquired pneumonia, 2019 update, from the Spanish Society of Pulmonology and Thoracic Surgery (Arch Bronconeumol 2020;56 Suppl 1:11-19).

Drug Shortages (US)

• Antimicrobial drugs or vaccines in reduced supply or unavailable (as of April 8, 2020) due to increased demand, manufacturing delays, product discontinuation by a specific manufacturer, or unspecified reasons:
  • [New on the list since March 20]: Doxycycline injection, Tobramycin lyophilized powder for injection
  • [Shortage recently resolved]: Acyclovir injection, Dalfopristin-Quinupristin injection, Daptomycin injection, Erythromycin lactobionate injection
  • [Continue to be in reduced supply]
    • Aminoglycosides: Amikacin injection, Gentamicin injection, Gentamicin ophthalmic ointment (unavailable), Tobramycin injection
    • Benzylpenicilloyl polylysine (Pre-Pen)
    • Carbapenems: Meropenem injection
    • Cephalosporins: Cefazolin injection, Cefepime injection, Cefotaxime injection (FDA is allowing temporary importation of product from SteriMax in Canada, in conjunction with Apollo Pharmaceuticals and its distributor FFF Enterprises. Click here for details), Cefoxitin injection, Ceftazidime injection, Ceftazidime/avibactam injection, Cefuroxime injection
    • Clindamycin injection
    • Fluoroquinolones: Ciprofloxacin 0.3% ophthalmic solution, Gemifloxacin tablets
    • Glycopeptides, glycolipopeptides, lipopeptides: Vancomycin injection
    • Macrolides/azalides: Azithromycin injection, Azithromycin ophthalmic solution 1% (unavailable)
    • Methanamine hippurate tablets
    • Nitrofurantoin oral suspension
    • Nitroimidazoles: None
    • Penicillins: Ampicillin/sulbactam injection, Piperacillin/tazobactam injection
    • Tetracyclines: None
    • Topical (miscellaneous) antibacterials: Bacitracin ophthalmic ointment, Mupirocin calcium 2% cream, Mupirocin calcium 2% nasal ointment (unavailable), Neomycin and Polymyxin B sulfates GU irrigant, Neomycin and Polymyxin B sulfates and Dexamethasone ophthalmic ointment, Sulfacetamide 10%/Prednisolone 0.2% ophthalmic ointment (unavailable), Sulfanilamide 15% vaginal cream (unavailable)
    • Antifungal drugs: Clotrimazole 10 mg oral troches, Fluconazole injection, Griseofulvin oral tablets and suspension
    • Antiparasitic drugs: Chloroquine tablets, Hydroxychloroquine tablets, Pentamidine isethionate
    • Antiretroviral drugs: None
    • Antiviral drugs: Cidofovir injection
    • Vaccines: Hepatitis B vaccine recombinant, Zoster vaccine recombinant (Shingrix), Yellow Fever vaccine (YF-VAX is unavailable, but Stamaril can be obtained through a limited number of clinics in the US. Click here).

• Antimicrobial drugs newly discontinued: 
  • Recent discontinuations: Bacitracin inection (in February 2020), Interferon alfa-2b (Intron A, in October 2019), Quinidine gluconate IV (in December 2017), Terbinafine granules (in May 2017), MenHibrix (in February 2017), Elvitegravir (Vitekta, in December 2016), Peginterferon alfa-2b (in February 2016; 50 mcg vials still available in limited quantities), Boceprevir (in December 2015), Permethrin 1% topical lotion (in September 2015).

• For detailed information including estimated resupply dates, see https://www.ashp.org/Drug-Shortages/

Sanford Guide ID Update features current developments in infectious diseases, curated by the Sanford Guide Editorial Board. Links marked with an asterisk (*) provide details to Web Edition subscribers, while all other links are universal. If you received this message from a colleague, subscribe now.
 

MARCH 24, 2020

SARS-CoV-2 / COVID-19

• Sanford Guide SARS-CoV-2 / COVID-19 material is freely available to all for the course of the pandemic. Click the link above.
• We advocate STAY AT HOME except for essential activities, e.g., food, medicines, healthcare and essential work such as police, fire, sanitation and healthcare.
• AVOID CROWDS  AND/OR CONGESTED AREAS. AVOID COMPLACENCY!

2020 Sanford Guides

• We anticipate that 2020 print editions of The Sanford Guide to Antimicrobial Therapy will become available in the coming weeks. To receive a notice as soon as the books are released, sign up here.

New or Updated Treatment Guidelines

• Clinical practice guideline for the diagnosis and treatment of Clostridioides difficile* infection, from the Spanish Society of Chemotherapy, Spanish Society of internal Medicine, and the working group of Postoperative Infection of the Spanish Society of Anesthesia and Reanimation (Rev Esp Quimioter 2020 Feb 20 [Epub ahead of print]). This CPG is available for download on the journal website.
• Guidelines for the treatment of Clostridioides difficile* infection in Taiwan, from the 2018 Guidelines Recommendations for Evidence-based Antimicrobial agents use in Taiwan working group, endorsed by Infectious Diseases Society of Taiwan (J Microbiol Immunol Infect 2020 Feb 14 [Epub ahead of print]). The guidelines are available on the journal website.
• Updated guidelines for the diagnosis and treatment of pelvic inflammatory diseases*, issued jointly by the French National College of Gynecologists and Obstetricians and the French-language Society for Infectious Diseases (J Gynecol Obstet Hum Reprod 2020 Feb 20 [Epub ahead of print]).
• Revised consensus guidelines for therapeutic monitoring of vancomycin* for serious MRSA* infections, from the ASHP, IDSA, the Pediatric Infectious Diseases Society (PIDS), and SIDP (Am J Health Syst Pharm 2020 Mar 19 [Epub ahead of print]). These guidelines update the 2009 release and are available for download on the journal website.

Drug Shortages (US)

• Antimicrobial drugs or vaccines in reduced supply or unavailable (as of March 20, 2020) due to increased demand, manufacturing delays, product discontinuation by a specific manufacturer, or unspecified reasons:
  • [New on the list since February 8]: Benzylpenicilloyl polylysine (Pre-Pen), Ceftazidime/avibactam, Chloroquine tablets, Gemifloxacin tablets, Gentamicin injection, Hydroxychloroquine tablets, Methenamine hippurate tablets, Neomycin and Polymyxin B sulfates and Dexamethasone ophthalmic ointment
  • [Shortage recently resolved]: Erythromycin 0.5% ophthalmic ointment, Metronidazole injection, Tuberculin (PPD)
  • [Continue to be in reduced supply]
    • Aminoglycosides: Amikacin injection, Gentamicin ophthalmic ointment (unavailable), Tobramycin injection
    • Carbapenems: Meropenem injection
    • Cephalosporins: Cefazolin injection, Cefepime injection, Cefotaxime injection (FDA is allowing temporary importation of product from SteriMax in Canada, in conjunction with Apollo Pharmaceuticals and its distributor FFF Enterprises. Click here for details), Cefoxitin injection, Ceftazidime injection, Cefuroxime injection
    • Clindamycin injection
    • Fluoroquinolones: Ciprofloxacin 0.3% ophthalmic solution, Gemifloxacin tablets
    • Glycopeptides, glycolipopeptides, lipopeptides: Daptomycin injection, Vancomycin injection
    • Macrolides/azalides: Azithromycin injection, Azithromycin ophthalmic solution 1% (unavailable), Erythromycin lactobionate injection
    • Nitrofurantoin oral suspension
    • Nitroimidazoles: None
    • Penicillins: Ampicillin/sulbactam injection, Piperacillin/tazobactam injection
    • Tetracyclines: None
    • Topical (miscellaneous) antibacterials: Bacitracin ophthalmic ointment, Mupirocin calcium 2% cream, Mupirocin calcium 2% nasal ointment (unavailable), Neomycin and Polymyxin B sulfates GU irrigant, Sulfacetamide 10%/Prednisolone 0.2% ophthalmic ointment (unavailable), Sulfanilamide 15% vaginal cream (unavailable)
    • Antifungal drugs: Clotrimazole 10 mg oral troches, Fluconazole injection, Griseofulvin oral tablets and suspension
    • Antiparasitic drugs: Pentamidine isethionate
    • Antiretroviral drugs: None
    • Antiviral drugs: Acyclovir injection, Cidofovir injection
    • Vaccines: Hepatitis B vaccine recombinant, Zoster vaccine recombinant (Shingrix), Yellow Fever vaccine (YF-VAX is unavailable, but Stamaril can be obtained through a limited number of clinics in the US. Click here).

• Antimicrobial drugs newly discontinued: 
  • Recent discontinuations: Bacitracin inection (in February 2020), Interferon alfa-2b (Intron A, in October 2019), Quinidine gluconate IV (in December 2017), Terbinafine granules (in May 2017), MenHibrix (in February 2017), Elvitegravir (Vitekta, in December 2016), Peginterferon alfa-2b (in February 2016; 50 mcg vials still available in limited quantities), Boceprevir (in December 2015), Permethrin 1% topical lotion (in September 2015).

• For detailed information including estimated resupply dates, see https://www.ashp.org/Drug-Shortages/

Sanford Guide ID Update features current developments in infectious diseases, curated by the Sanford Guide Editorial Board. Links marked with an asterisk (*) provide details to Web Edition subscribers, while all other links are universal. If you received this message from a colleague, subscribe now.
 

MARCH 2020

Given the current SARS-CoV-2 situation, Sanford Guide is releasing this special ID Update with the latest information. A more comprehensive ID Update will be released later this month.
 

SARS-CoV-2*

• CDC Health Alert Network (HAN) No. 428: Update and Interim Guidance on Outbreak of Coronavirus Disease 2019 (COVID-19). This is classified as a Health Update and is available on the CDC website.
• Insights and concise update of current situation: JAMA 2020 Feb 28 [Epub ahead of print].
• Detailed clinical and epidemiologic description of the first 425 cases reported in Wuhan (N Engl J Med 2020 Jan 29 [Epub ahead of print]) with an associated editorial from Fauci et al (N Engl J Med 2020 Feb 28 [Epub ahead of print]).
• Perspective from Bill Gates: N Engl J Med 2020 Feb 28 [Epub ahead of print].

Sanford Guide ID Update features current developments in infectious diseases, curated by the Sanford Guide Editorial Board. Links marked with an asterisk (*) provide details to Web Edition subscribers, while all other links are universal. If you received this message from a colleague, subscribe now.
 

FEBRUARY 2020

SARS-CoV-2

• WHO officially names the virus 2019-nCoV as SARS-CoV-2*. The disease caused by the virus is named COVID-19.
• Rapid advice guideline for the diagnosis and treatment of 2019-nCoV pneumonia, prepared in accordance with the methodology and general rules of WHO Guideline Development and the WHO Rapid Advice Guidelines (Mil Med Res 2020;7:4). The guidelines are available on the journal website.

New or Updated Treatment Guidelines

• Clinical practice guidelines for the prevention and management of viral hepatitis in inflammatory bowel disease, from the Korean Association for the Study of Intestinal Diseases (Intest Res 2020;18:18). The guidelines are available on the journal website.
• S2k guidelines for the diagnosis and treatment of herpes zoster and postherpetic neuralgia (J Dtsch Dermatol Ges 2020;18:55). These guidelines were developed on behalf of the German Herpes Management Forum under the auspices of the Paul Ehrlich Society of Chemotherapy.
• Surviving Sepsis Campaign international guidelines for the management of septic shock and sepsis-associated organ dysfunction in children, from the Society of Critical Care Medicine and the World Federation of Pediatric Intensive and Critical Care Societies (Pediatr Crit Care Med 2020;21:e52). The guidelines are available on the journal website.
• Clinical practice guidelines for the management of vascular graft and stent graft infections, from the European Society for Vascular Surgery (Eur J Vasc Endovasc Surg 2020 Jan 30 [Epub ahead of print]).

From CDC

• At its October 2019 meeting, the Advisory Committee on Immunization Practices (ACIP) voted to approve the 2020 Recommended Child and Adolescent Immunization Schedule for Ages 18 Years or Younger, and the 2020 Recommended U.S. Adult Immunization Schedule for Persons Aged 19 Years and Older. Tables and accompanying notes can be found on the CDC website.
• Guidelines for the treatment of latent tuberculosis infection, from the National Tuberculosis Controllers Association and CDC (MMWR Recomm Rep 2020;69(No. RR-1):1–11). The guidelines are available on the CDC website.

From FDA

• The US FDA has requested that all current manufacturers of bacitracin for injection voluntarily withdraw their product from the market. Based on FDA’s review of currently available data, FDA believes that the potential problems associated with bacitracin for injection are sufficiently serious to remove the drug from the market. This requested voluntary withdrawal does not impact approved topical or ophthalmic drugs that contain bacitracin. More information can be found here.

Drug Shortages (US)

• Antimicrobial drugs or vaccines in reduced supply or unavailable (as of February 8, 2020) due to increased demand, manufacturing delays, product discontinuation by a specific manufacturer, or unspecified reasons:
  • [New on the list since January 5]: Erythromycin 0.5% ophthalmic ointment
  • [Shortage recently resolved]: Doxycycline hyclate injection, Letermovir injection, Rabies immune globulin, Rabies vaccine
  • [Continue to be in reduced supply]
    • Aminoglycosides: Amikacin injection, Gentamicin ophthalmic ointment (unavailable), Tobramycin injection
    • Carbapenems: Meropenem injection
    • Cephalosporins: Cefazolin injection, Cefepime injection, Cefotaxime injection (FDA is allowing temporary importation of product from SteriMax in Canada, in conjunction with Apollo Pharmaceuticals and its distributor FFF Enterprises. Click here for details), Cefoxitin injection, Ceftazidime injection, Cefuroxime injection
    • Clindamycin injection
    • Fluoroquinolones: Ciprofloxacin 0.3% ophthalmic solution, Gemifloxacin tablets
    • Glycopeptides, glycolipopeptides, lipopeptides: Daptomycin injection, Vancomycin injection
    • Macrolides/azalides: Azithromycin injection, Azithromycin ophthalmic solution 1% (unavailable), Erythromycin lactobionate injection
    • Nitrofurantoin oral suspension
    • Nitroimidazoles: Metronidazole injection
    • Penicillins: Ampicillin/sulbactam injection, Piperacillin/tazobactam injection
    • Tetracyclines: None
    • Topical (miscellaneous) antibacterials: Bacitracin ophthalmic ointment (unavailable), Mupirocin calcium 2% cream, Mupirocin calcium 2% nasal ointment (unavailable), Neomycin and Polymyxin B sulfates GU irrigant, Sulfacetamide 10%/Prednisolone 0.2% ophthalmic ointment, Sulfanilamide 15% vaginal cream (unavailable)
    • Antifungal drugs: Clotrimazole 10 mg oral troches, Fluconazole injection, Griseofulvin oral tablets and suspension
    • Antiparasitic drugs: Pentamidine isethionate
    • Antiretroviral drugs: None
    • Antiviral drugs: Acyclovir injection, Cidofovir injection
    • Vaccines: Hepatitis B vaccine recombinant, Zoster vaccine recombinant (Shingrix), Yellow Fever vaccine (YF-VAX is unavailable, but Stamaril can be obtained through a limited number of clinics in the US. Click here).

• Antimicrobial drugs newly discontinued: 
  • Recent discontinuations: Interferon alfa-2b (Intron A, in October 2019), Quinidine gluconate IV (in December 2017), Terbinafine granules (in May 2017), MenHibrix (in February 2017), Elvitegravir (Vitekta, in December 2016), Peginterferon alfa-2b (in February 2016; 50 mcg vials still available in limited quantities), Boceprevir (in December 2015), Permethrin 1% topical lotion (in September 2015).

• For detailed information including estimated resupply dates, see https://www.ashp.org/Drug-Shortages/